CClinicalTrials.gg
CompletedNCT00611416Updated Feb 9, 2009

The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism

An interventional study of green tea and Mix of catechins and caffeine in Obesity, sponsored by University of Copenhagen. Completed at 1 site in Denmark. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-02-09.

Sponsored by University of Copenhagen · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

The aim of this study is to elucidate the role of specific catechins, a mixture of catechins and caffeine in relation to weight control with particular emphasis on energy metabolism and fat oxidation.

Read the detailed description

Obesity is the result of an imbalance between energy intake (EI) and energy expenditure (EE). Thus, two ways to treat obesity are to reduce EI or increase EE. Bioactive food ingredients affecting energy metabolism, e.g. EE, fat oxidation, satiety and EI may help people to successfully control or manage their weight. Green tea, one of the most widely consumed beverages in the world, may possess beneficial effects on the treatment of obesity.

Green tea is made from the leaves of Camellia sinensis species of the Theaceae family. Green tea is the non- fermented/oxidised products, in contrast to black tea that is fully fermented/oxidised. Green teas contain high quantities of catechins and caffeine which are believed to be the active components affecting energy metabolism. EGCG is the most abundant catechin and has received the most attention (Yang et al., 2000). Caffeine represents approximately 3 to 5 % of the dry weight of green tea (Dufresne et al., 2001, Yang et al., 2000). It is general accepted that caffeine consumption is related to an increase in EE (Astrup et al., 1990), whereas the relation between catechins and energy metabolism is recently discovered.

In a study by Dulloo et al (1999), ten healthy men were assigned to 3 treatments: 1) green tea extract containing 150 mg/day caffeine and 270 mg/day of EGCG, 2) caffeine (150 mg/day) or 3) placebo. Ingestion of green tea extract (taken with each meal) increased 24-h EE by 4 % (328 kJ), reflecting its stimulatory effect on thermogenesis. This study also found a reduction in the respiratory quotient (RQ) during the green tea extract treatment, suggesting an increase in fat oxidation. However, Kovacs et al. (2004) did not report any changes in 24-h EE or RQ after same supplementation with green tea capsules, which may be explained by different background caffeine consumption.

Recently, two medium term studies have reported of increased fat oxidation after 8 and 12 weeks, respectively, supplementation with tea catechin containing beverage (Ota et al., 2005, Harada et al., 2005). In addition, Nagao et al. (2005) have shown that a daily consumption of tea beverage containing 690 mg/day catechins for 12 weeks reduced body fat area by 8% compared to the control group. Thus, catechins may not only promote EE, but also mildly reduce body fat.

Several potential mechanisms responsible for the altered energy and fat metabolism have been proposed. Dulloo et al. (1999) have suggested a synergistic interaction between catechins and caffeine due to sympathetically released noradrenaline (NA). Since catechins are known to be capable of inhibiting catechol O-methyltransferase (COMT) (the enzyme that degrades NA) (Borchardt \& Huber, 1975), and caffeine to inhibit trancellular phosphodiesterases (enzymes that break down NA-induced cAMP), it is proposed that the green tea extract, via its catechins polyphenols and caffeine, is effective in stimulating thermogenesis by relieving inhibition at different control points along the NA-cAMP axis. Taken together, both caffeine and tea catechins would be expected to increase and/or prolong the stimulatory effects of norepinephrine on energy and lipid metabolism.

Several animal studies have been conducted to elucidate the anti-obese mechanisms of green tea extracts.

  • Increased hepatic β-oxidation of fatty acids in mice after 4 weeks high fat diet with supplementation with tea catechins (74% EGCg, 18% ECg, 6% GCg, 2% others) (Murase et al., 2002 and 4 weeks high fat diet with supplementation with EGCg (Klaus et al., 2005). On the other hand, fatty acid synthase (FAS) was not altered by tea catechins, which may indicate that the simulation of fatty acid oxidation, rather than suppression of lipogenesis, is the predominant contribution (Murase et al., 2002).
  • Modulated appetite and reduces food intake through the leptin receptor-independent pathway (Kao et al., 2000)
  • Intraperitoneal administration of EGCg may reduce the diet digestibility resulting in increased faecal excretion of lipids (Klaus et al., 2005)
  • Green tea extract (8% caffeine and 25% catechins (\~70% EGCg)) stimulates brown adipose tissue thermogenesis and energy expenditure, which may be due to the prolonged effect of noradrenalin (Dulloo et al., 2000).

Large variations in catechin content and chemical structures occur during preparation and manufacturing of green tea products and therefore also among the studies. EGCg is the most intensely studied catechin. However, the plasma bioavailability of EGCg is lower than of EGC and EG (Henning et al., 2004), suggesting that non-galloylated catechins are better absorbed than the galloylated (Manach et al., 2005).

In addition, it is not known whether epimerization of catechins alters the effect on energy and fat metabolism (Harada et al., 2005, Ota et al., 2005, Xu et al., 2004). Therefore, it is not clear whether the reported effects are due to the total quantity of catechins, the chemical structure of specific catechins (e.g. epimerization and galloylation), and/or the caffeine content or other components of in the mix.

Methods

The study is a 5-way crossover double blind placebo controlled design. At each test day, energy expenditure and fat oxidation are measured via indirect calorimetry for 13 hours in one of two whole body respiratory chambers.

02

Conditions studied

  • Obesity

Keywords

  • catechins
  • caffeine
  • energy expenditure
  • fat oxidation
  • appetite
03

In context

Lead sponsor

University of Copenhagen is the lead sponsor of 450 studies on the registry; 61 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy men
  • Age 18-40 years
  • BMI 18,5-25 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Diabetes or any other endocrinological disease
  • Hypertensive medication
  • Increased Blood Pressure > 140/85
  • Hyperlpidimia
  • Chronic disease (i.e. HIV)
  • Use of any diet supplements including vitamins (during and 3 months prior to the study).
  • High alcohol intake (>21 units a week)
  • High caffeine intake (>250 mg/day) or high catechin intake (>200 mg/day)
  • Smoking
  • Elite sports performer
  • Use of any regular medication
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    1

    Active treatment A

    Dietary Supplement: green tea · Dietary Supplement: Mix of catechins and caffeine

  • Experimental
    2

    Active treatment B

    Dietary Supplement: green tea · Dietary Supplement: EGCG

  • Experimental
    3

    Active treatment C

    Dietary Supplement: green tea · Dietary Supplement: EGC

  • Active comparator
    4

    Positive control

    Dietary Supplement: Caffeine

  • Placebo comparator
    5

    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementgreen tea

    different catechin combinations

  • Dietary supplementMix of catechins and caffeine

    3 tablet a day

  • Dietary supplementEGCG

    3 tablets a day

    Also known as: epigallocatechin gallate

  • Dietary supplementEGC

    3 tablets a day

    Also known as: Epigallocatechin

  • Dietary supplementCaffeine

    3 tablets a day

  • Dietary supplementPlacebo

    3 tablets a day

06

What researchers measure

Primary outcomes

  1. fat oxidation

    Time frame: november 2007

Secondary outcomes

  1. appetite

    Time frame: november 2007

07

Study locations

1 site
  • Institute of Human Nutrition, The Royal Veterinary and Agricultrual University
    Frederiksberg C, 1958, Denmark
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 9, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00611416
Lead sponsor
University of Copenhagen
Collaborators
Unilever R&D
First posted
Feb 8, 2008
Start date
Nov 2005
Completion
Feb 2006
Last update
Feb 9, 2009

Study contacts

Arne Astrup, Proffessor
study chair · Insitute of Human Nutrition

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion